Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RN7SL492P** is a *pseudogene* encoding a non-coding RNA similar to the functional 7SL RNA, which forms the RNA component of the signal recognition particle complex important for cotranslational protein targeting to the endoplasmic reticulum[1][4][7][11][12]. The majority of 7SL-like sequences in the human genome, including RN7SL492P, are pseudogenes—genomic fragments derived from retrotransposition or duplication events—that do not give rise to functional transcripts or proteins[11][4][6]. While functional 7SL RNA plays essential roles in the SRP complex, 7SL pseudogenes typically lack biological function, although rare pseudogene RNAs can sometimes influence gene regulation through miRNA or RNA-binding protein interactions[5][8][10]. There is no evidence RN7SL492P itself is expressed or implicated in specific biological processes, disease mechanisms, or drug interactions. RN7SL492P is thus not a therapeutic target but rather a genomic fossil resulting from the evolutionary dissemination of 7SL RNA-like sequences[11]. **Additional notes:** - There is nothing intrinsically "misspelled" about this name, but it is not a druggable or classical biological target. - The RNA, 7SL, cytoplasmic 492, pseudogene gene is located on chromosome 4 and is annotated as "misc RNA" in genomic databases[4][7]. - Only rare pseudogenes have demonstrated impact on disease or gene regulation (e.g., via pseudogene-derived RNAs acting as decoys or competing endogenous RNAs), but this is not described for RN7SL492P[8][10]. **Key point:** RN7SL492P is a pseudogene and not considered a receptor, enzyme, transporter, or therapeutic target based on current knowledge.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 492, pseudogene (RN7SL492P).